Expected 2020-2021 Milestones Gamida Cell targets achieving the following milestones during 2020-2021: Omidubicel Present data from the Phase 3 study at a medical meeting in the second half of 2020 Submit the biologics license application to the FDA in the second half of 2020, assuming positive data Report additional data from the Phase 1/2 study in patients with severe aplastic anemia in the second half of 2020 Launch omidubicel in 2021, contingent upon FDA approval GDA-201 Present additional data from the Phase 1 study in the first half of 2020 Submit company-sponsored investigational new drug application to FDA in the second half of 2020 Initiate a Phase 1/2 clinical study in patients with non-Hodgkin lymphoma in 2021 https://www.businesswire.com/news/home/20200113005222/en/Gamida-Cell-Announces-2020-Goals-Company-Update